Accessible Unlicensed Requires Authentication Published by De Gruyter August 11, 2015

Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study

Sivasankar Devanarayanan, Hanumanthappa Nandeesha, Shivanand Kattimani and Siddharth Sarkar

Abstract

Background: Deregulation of synaptic plasticity and oxidative stress are reported to play a crucial role in the pathogenesis of schizophrenia. Matrix metalloproteinase-9 (MMP-9) is an extracellular protease involved in regulation of synaptic plasticity. Malondialdehyde (MDA) is a marker of lipid peroxidation which is elevated in schizophrenia. Earlier studies have reported polymorphism of MMP-9 and its association with schizophrenia. The present study was designed to assess the serum levels of MMP-9, MDA and total antioxidant status (TAS) and their association in schizophrenia.

Methods: A total of 40 cases and 40 controls were included in the study. Serum MMP-9, MDA and TAS were estimated in all the subjects. Disease severity was assessed using Positive and Negative Syndrome Scale (PANSS).

Results: MMP-9 and MDA were significantly increased and TAS were significantly reduced in schizophrenia cases compared to controls. MMP-9 was positively correlated with MDA (r=0.353, p=0.025) and negatively correlated with TAS (r=−0.461, p=0.003). TAS was significantly correlated with total (r=0.322, p=0.043) and negative symptom scores (r=0.336, p=0.034). Higher MMP-9 levels were associated with previous exposure to antipsychotics (p=0.032).

Conclusions: MMP-9 and oxidative stress were increased and correlate well with each other in schizophrenia cases. Though total oxidant status showed positive association with disease severity, MMP-9 and MDA were not associated with the severity of the disease.


Corresponding author: Hanumanthappa Nandeesha, Assistant Professor, Department of Biochemistry, JIPMER, Puducherry, India, Phone: +91 9443434438, Fax: +91 0413 2272067, E-mail:

Acknowledgments

This work was supported by a grant from JIPMER intramural fund sanctioned to the corresponding author.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull 2009;35:493–508. Search in Google Scholar

2. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012;46:819–24. Search in Google Scholar

3. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007;85:2813–23. Search in Google Scholar

4. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 2013;139:32–40. Search in Google Scholar

5. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 2006;26:1923–34. Search in Google Scholar

6. Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, et al. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 2007;62:359–62. Search in Google Scholar

7. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001;124:1734–42. Search in Google Scholar

8. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008;180:1021–35. Search in Google Scholar

9. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11;851–76. Search in Google Scholar

10. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011;15:2011–35. Search in Google Scholar

11. Mahadik S P, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463–93. Search in Google Scholar

12. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1–10. Search in Google Scholar

13. Fukunaga K, Yoshida M, Nakazono N. A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high-performance liquid chromatography. Biomed Chromatogr 1998;12:300–3. Search in Google Scholar

14. Boskovic M, Vovk T, Plesnicar BK, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011;9:301–12. Search in Google Scholar

15. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003;121:109–22. Search in Google Scholar

16. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003;69:393–9. Search in Google Scholar

17. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009;60:87–93. Search in Google Scholar

18. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006;60:458–64. Search in Google Scholar

19. Agarwal R, Chase SD. Rapid fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002;775:121–6. Search in Google Scholar

20. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’ the FRAP assay. Anal Biochem 1996;239:70–6. Search in Google Scholar

21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76. Search in Google Scholar

22. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 2013;28:391–403. Search in Google Scholar

23. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 1996;3:69–75. Search in Google Scholar

24. Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J 2002;21:6643–8. Search in Google Scholar

25. Groszewska A, Kapelski P, Skibińska M, Hauser J. Family based association study of MMP-9 gene-1562 C & gt;T polymorphism in schizophrenia. Psychiatr Pol 2011;45:317–24. Search in Google Scholar

26. Han H, He X, Tang J, Liu W, Liu K, Zhang J, et al. The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res 2011;190:163–4. Search in Google Scholar

27. Yamamori H1, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett 2013;556:37–41. Search in Google Scholar

28. Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res 2014;215:268–73. Search in Google Scholar

29. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006;59:929–39. Search in Google Scholar

30. Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry 2015;77:52–8. Search in Google Scholar

31. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572–9. Search in Google Scholar

32. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003;24:2180–5. Search in Google Scholar

33. Stawarski M, Stefaniuk M, Wlodarczyk J. Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines. Front Neuroanat 2014;8:1–15. Search in Google Scholar

Received: 2015-3-5
Accepted: 2015-7-6
Published Online: 2015-8-11
Published in Print: 2016-3-1

©2016 by De Gruyter